Systemic Lupus Erythematous

Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to patients with lupus and other rheumatic diseases, the cells currently in use remain “old fashioned,” according to a speaker.

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that impact quality of life, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.